CN104352455A - Cefalexin injection - Google Patents

Cefalexin injection Download PDF

Info

Publication number
CN104352455A
CN104352455A CN201410657883.3A CN201410657883A CN104352455A CN 104352455 A CN104352455 A CN 104352455A CN 201410657883 A CN201410657883 A CN 201410657883A CN 104352455 A CN104352455 A CN 104352455A
Authority
CN
China
Prior art keywords
injection
cefalexin
fatty acid
ethyl cellulose
smooth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201410657883.3A
Other languages
Chinese (zh)
Inventor
李良洪
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CHONGQING TAITONG ANIMAL PHARMACEUTICAL Co Ltd
Original Assignee
CHONGQING TAITONG ANIMAL PHARMACEUTICAL Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CHONGQING TAITONG ANIMAL PHARMACEUTICAL Co Ltd filed Critical CHONGQING TAITONG ANIMAL PHARMACEUTICAL Co Ltd
Priority to CN201410657883.3A priority Critical patent/CN104352455A/en
Publication of CN104352455A publication Critical patent/CN104352455A/en
Pending legal-status Critical Current

Links

Landscapes

  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention discloses a method for preparing a cefalexin injection. The injection contains the ingredients in parts by weight: 2-5 parts of cefalexin, 1-5 parts of PVC, 1-2 parts of ethyl cellulose, 1-3 parts of lecithin, 0.5-1 part of fatty acid sorbitan, 0.5-1 part of polysorbate and 1-3 parts of PEG. The injection is high in drug stability, good in solubility and simple in preparation process.

Description

A kind of cefalexin injection
Technical field
The present invention relates to a kind of animal-use drug, particularly relate to a kind of preparation method of cefalexin injection.
Background technology
Cefalexin chemical name is: (6R, 7R)-3-methyl-7-[(R)-2-amino-2-phenylacetylamino]-8-oxo-5-thia-1-azabicyclo [4.2.0] oct-2-ene-2-formic acid-hydrate.Cefalexin belongs to first generation cephalosporin, except Enterococcus, methicillin-resistant Staphylococci, and streptococcus pneumoniae, Hemolytic streptococcus, product or not produce the staphylococcic most of bacterial strain of penicillinase responsive to this product.This product has better antibacterial action to neisseria, but the sensitivity of hemophilus influenza to this product is poor; This product has certain antibacterial action to part escherichia coli, proteus mirabilis, salmonella and shigella dysenteriae.All the other enterobacteriaceae lactobacteriaceaes, acinetobacter calcoaceticus, Pseudomonas aeruginosa, bacteroides fragilis all present drug resistance to this product.Fusobacterium and Wei Rong coccus are generally responsive to this product, and anaerobism gram positive coccus is to this product medium sensitivity.Be applicable to the respiratory tract infection such as the acute tonsillitis caused by sensitive organism, angina, otitis media, sinusitis, bronchitis, pneumonia, urinary tract infection and skin soft-tissue infection etc.This product is dissolved in methanol/ethanol, does not dissolve in water.
Cefalexin is used for the treatment of animal body by the present invention.
Summary of the invention
The invention provides a kind of preparation method of cefalexin injection; This injection has the features such as solubility is good, good stability, and drug loading is high, safety of clinical trials is good, overcomes the deficiencies in the prior art part.
In injection, the ratio of each component is cefalexin 1-5 part; PVC1-5 part; Ethyl cellulose 1-2 part; Lecithin 1-3 part; The smooth 0.5-1 part of fatty acid Pyrusussuriensis; Polysorbate 0.5-1 part; PEG1-3 part.
Described PVC molecular weight is between 5000-20000.
As preferably, emulsifying agent is the mixture of the smooth and Polysorbate of fatty acid Pyrusussuriensis, and its ratio is than being 0.5:1-1:2.
As preferably, PVC is 3-5 part.
As preferably, fatty acid Pyrusussuriensis used is smooth is fatty acid Pyrusussuriensis smooth 80,40,20; Polysorbate is polyoxyethylene sorbitan monoleate, 40,20.
As preferably, ethyl cellulose is selected from ethyl cellulose-4000 or ethyl cellulose-6000.
The preparation method of above-mentioned injection cefalexin, comprises the steps:
(1) each component is taken by formula proportion;
(2) cefalexin and ethyl cellulose, lecithin add in water for injection successively, and stirring and dissolving obtains interior aqueous phase W1;
(3) PVC, fatty acid Pyrusussuriensis is smooth and Polysorbate is dissolved in volume ratio is in the dichloromethane/acetone of 3: 1, obtains oil phase;
(4) PEG adds in water for injection to be stirred to and dissolves completely, obtains outer aqueous phase W2;
(5) under agitation slowly added in oil phase by W1, under ice bath, supersound process 20s obtains colostrum; Slowly added in W2 by colostrum and stir 10min and obtain emulsion, poured into by emulsion in the aqueous solution for injection of sodium chloride, ice bath stirs 4h volatile residue organic solvent, and collect microsphere by 0.45 μm of filtering with microporous membrane, water for injection washs 3 times, vacuum lyophilization.
Detailed description of the invention
Embodiment 1: a kind of injection cefalexin
Cefalexin 500g;
PVC400g;
Ethyl cellulose 100g;
Lecithin 100g;
The smooth 2050g of fatty acid Pyrusussuriensis;
Polysorbate 40 50g;
PEG100g;
Cefalexin, ethyl cellulose and lecithin are added successively in 1000mL water for injection, stirring and dissolving obtains interior aqueous phase W1; It is in the 1000mL dichloromethane/acetone of 3: 1 that smooth for fatty acid Pyrusussuriensis 20, polysorbate 40 are dissolved in volume ratio, obtains oil phase; PEG is added in water for injection to be stirred to and dissolve completely, obtain outer aqueous phase W2; Under agitation slowly added in oil phase by W1, under ice bath, supersound process 20s obtains colostrum; Colostrum is slowly added in W2 and stirs 10min and obtain emulsion, poured into by emulsion in the aqueous solution for injection of 1000mL sodium chloride, ice bath stirs 4h volatile residue organic solvent, collects microsphere by 0.45 μm of filtering with microporous membrane, water for injection washs 3 times, vacuum lyophilization.
Embodiment 2: a kind of injection cefalexin
Cefalexin 300g;
PVC200g;
Ethyl cellulose 300g;
Lecithin 200g
The smooth 8050g of fatty acid Pyrusussuriensis;
Polysorbate 40 50g;
PEG50g。
Cefalexin, ethyl cellulose and lecithin are added successively in 1000mL water for injection, stirring and dissolving obtains interior aqueous phase W1; It is in the 1000mL dichloromethane/acetone of 3: 1 that smooth for fatty acid Pyrusussuriensis 20, polysorbate 40 are dissolved in volume ratio, obtains oil phase; PEG is added in water for injection to be stirred to and dissolve completely, obtain outer aqueous phase W2; Under agitation slowly added in oil phase by W1, under ice bath, supersound process 20s obtains colostrum; Colostrum is slowly added in W2 and stirs 10min and obtain emulsion, poured into by emulsion in the aqueous solution for injection of 1000mL sodium chloride, ice bath stirs 4h volatile residue organic solvent, collects microsphere by 0.45 μm of filtering with microporous membrane, water for injection washs 3 times, vacuum lyophilization.
Embodiment 3: a kind of injection cefalexin
Cefalexin 400g;
PVC100g;
Ethyl cellulose 100g;
Lecithin 100g
The smooth 2050g of fatty acid Pyrusussuriensis;
Polyoxyethylene sorbitan monoleate 50g;
Glycerol 100g;
Cefalexin, ethyl cellulose and lecithin are added successively in 1000mL water for injection, stirring and dissolving obtains interior aqueous phase W1; It is in the 1000mL dichloromethane/acetone of 3: 1 that smooth for fatty acid Pyrusussuriensis 20, polysorbate 40 are dissolved in volume ratio, obtains oil phase; PEG is added in water for injection to be stirred to and dissolve completely, obtain outer aqueous phase W2; Under agitation slowly added in oil phase by W1, under ice bath, supersound process 20s obtains colostrum; Colostrum is slowly added in W2 and stirs 10min and obtain emulsion, poured into by emulsion in the aqueous solution for injection of 1000mL sodium chloride, ice bath stirs 4h volatile residue organic solvent, collects microsphere by 0.45 μm of filtering with microporous membrane, water for injection washs 3 times, vacuum lyophilization.
Embodiment 4: droplet measurement
The injection of Example 1-3, is dissolved in water into the solution of every 1mL containing 1mg cefalexin, measures with laser diffraction particle size instrument.The cefalexin injection that acetonideexample 1-3 prepares is spherical shape, and even particle size distribution, whole particle diameter is between 300-550nm.
Embodiment 5: envelop rate detects
The injection of cefalexin is dissolved in water into the solution of every 1mL containing cefalexin 1mg, with the centrifugation 15min of 6000r/min, gets supernatant 1mL, with dissolve with ethanol, measure the content of cefalexin.
Dose in envelop rate=microsphere/(dose in the dose+medium in microsphere) × 100%
The envelop rate of injection prepared by embodiment 1-3, between 80%-90%.
Embodiment 6: dissolution velocity is investigated
Each two bottles of injection in random selecting embodiment 1-3, numbering 1-6, sample number into spectrum 7 after physical mixed, the cefalexin freeze-dried powder numbering 8 of having gone on the market, by the dissolving method of clinical application, inject 10mL water for injection respectively, eddy mixer jolts, completely clear and bright for index to dissolve, calculate dissolution velocity.
Experimental result shows that the dissolution velocity of injection of the present invention is obviously better than the injection of direct packaging.
Embodiment 7: study on the stability
The injection that the sample prepared by embodiment 1-3 and raw material directly mix subpackage is placed in high temperature 40 DEG C, lower 6 months of relative humidity 75% ± 5% condition respectively, carries out acceleration and investigates.

Claims (6)

1. a cefalexin injection, is characterized in that the parts by weight of component are:
Cefalexin 1-5 part;
PVC1-5 part;
Ethyl cellulose 1-2 part;
Lecithin 1-3 part;
The smooth 0.5-1 part of fatty acid Pyrusussuriensis;
Polysorbate 0.5-1 part;
PEG1-3 part;
Described PVC molecular weight is between 5000-20000.
2. pharmaceutical composition as claimed in claim 1, it is characterized in that described emulsifying agent is the mixture of the smooth and Polysorbate of fatty acid Pyrusussuriensis, its ratio is than being 0.5:1-1:2.
3. pharmaceutical composition as claimed in claim 1, is characterized in that PVC is 3-5 part.
4. pharmaceutical composition as claimed in claim 1, it is characterized in that fatty acid Pyrusussuriensis used smooth be fatty acid Pyrusussuriensis smooth 80,40,20; Polysorbate is polyoxyethylene sorbitan monoleate, 40,20.
5. pharmaceutical composition as claimed in claim 1, is characterized in that described ethyl cellulose is selected from ethyl cellulose-4000 or ethyl cellulose-6000.
6. the preparation method of injection cefalexin as described in claim arbitrary in claim 1-5, comprises the steps:
(1) each component is taken by formula proportion;
(2) cefalexin and ethyl cellulose, lecithin add in water for injection successively, and stirring and dissolving obtains interior aqueous phase W1;
(3) PVC, fatty acid Pyrusussuriensis is smooth and Polysorbate is dissolved in volume ratio is in the dichloromethane/acetone of 3: 1, obtains oil phase;
(4) PEG adds in water for injection to be stirred to and dissolves completely, obtains outer aqueous phase W2;
(5) under agitation slowly added in oil phase by W1, under ice bath, supersound process 20s obtains colostrum; Slowly added in W2 by colostrum and stir 10min and obtain emulsion, poured into by emulsion in the aqueous solution for injection of sodium chloride, ice bath stirs 4h volatile residue organic solvent, and collect microsphere by 0.45 μm of filtering with microporous membrane, water for injection washs 3 times, vacuum lyophilization.
CN201410657883.3A 2014-11-13 2014-11-13 Cefalexin injection Pending CN104352455A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201410657883.3A CN104352455A (en) 2014-11-13 2014-11-13 Cefalexin injection

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201410657883.3A CN104352455A (en) 2014-11-13 2014-11-13 Cefalexin injection

Publications (1)

Publication Number Publication Date
CN104352455A true CN104352455A (en) 2015-02-18

Family

ID=52519832

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201410657883.3A Pending CN104352455A (en) 2014-11-13 2014-11-13 Cefalexin injection

Country Status (1)

Country Link
CN (1) CN104352455A (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107320452A (en) * 2017-07-07 2017-11-07 青岛农业大学 A kind of Lung targeting sulphuric acid cephalosporium quinol EC microballoons and preparation method thereof
CN107349180A (en) * 2017-09-13 2017-11-17 南通荣成医药化工有限公司 A kind of novel compound cefalexin parenteral solution
CN107412156A (en) * 2017-09-13 2017-12-01 南通荣成医药化工有限公司 A kind of compound cefalexin parenteral solution
CN107496430A (en) * 2017-09-13 2017-12-22 南通荣成医药化工有限公司 A kind of Cefradine pharmaceutical composition
CN107519173A (en) * 2017-09-13 2017-12-29 南通荣成医药化工有限公司 A kind of new Cefuroxime axetil pharmaceutical composition
CN107519174A (en) * 2017-09-13 2017-12-29 南通荣成医药化工有限公司 A kind of new compound preparation of ceftiofur sodium
CN107569489A (en) * 2017-09-13 2018-01-12 南通荣成医药化工有限公司 A kind of compound preparation of ceftiofur sodium
CN107582520A (en) * 2017-09-13 2018-01-16 南通荣成医药化工有限公司 A kind of new compound cefalexin parenteral solution
CN107583056A (en) * 2017-09-13 2018-01-16 南通荣成医药化工有限公司 A kind of Cefuroxime axetil pharmaceutical composition
CN107595801A (en) * 2017-09-13 2018-01-19 南通荣成医药化工有限公司 A kind of new Cefuroxime axetil pharmaceutical composition

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107320452A (en) * 2017-07-07 2017-11-07 青岛农业大学 A kind of Lung targeting sulphuric acid cephalosporium quinol EC microballoons and preparation method thereof
CN107320452B (en) * 2017-07-07 2020-04-28 青岛农业大学 Lung-targeting cefquinome sulfate EC microspheres and preparation method thereof
CN107349180A (en) * 2017-09-13 2017-11-17 南通荣成医药化工有限公司 A kind of novel compound cefalexin parenteral solution
CN107412156A (en) * 2017-09-13 2017-12-01 南通荣成医药化工有限公司 A kind of compound cefalexin parenteral solution
CN107496430A (en) * 2017-09-13 2017-12-22 南通荣成医药化工有限公司 A kind of Cefradine pharmaceutical composition
CN107519173A (en) * 2017-09-13 2017-12-29 南通荣成医药化工有限公司 A kind of new Cefuroxime axetil pharmaceutical composition
CN107519174A (en) * 2017-09-13 2017-12-29 南通荣成医药化工有限公司 A kind of new compound preparation of ceftiofur sodium
CN107569489A (en) * 2017-09-13 2018-01-12 南通荣成医药化工有限公司 A kind of compound preparation of ceftiofur sodium
CN107582520A (en) * 2017-09-13 2018-01-16 南通荣成医药化工有限公司 A kind of new compound cefalexin parenteral solution
CN107583056A (en) * 2017-09-13 2018-01-16 南通荣成医药化工有限公司 A kind of Cefuroxime axetil pharmaceutical composition
CN107595801A (en) * 2017-09-13 2018-01-19 南通荣成医药化工有限公司 A kind of new Cefuroxime axetil pharmaceutical composition

Similar Documents

Publication Publication Date Title
CN104352455A (en) Cefalexin injection
CN104382909A (en) Compound cefalexin injection
Piriyaprasarth et al. Flocculating and suspending properties of commercial citrus pectin and pectin extracted from pomelo (Citrus maxima) peel
CN106176617B (en) Amoxicillin soluble powder and preparation method thereof
CN105250242B (en) Include the film preparation and its production method of silaenafil free alkali
CN101036654B (en) Stable cefoperazone sulbactam medicine compound preparation
JPS5872516A (en) Novel composition for coating biologically active substance
BR102013016575A2 (en) PARTICULAR ANIMAL FEED SUPPLEMENTS WITH MEDICINAL PRODUCT AND METHODS FOR PREPARATION
CN104644629A (en) Ampicillin sodium sulbactam sodium preparation for injection and preparation method thereof
CN103446075B (en) A kind of Cefaclor Capsules and preparation method thereof
CN107595782A (en) A kind of Linezolid dry suspensoid agent and preparation method thereof
JPH037230A (en) Composition of vitamin b group compound and production thereof
CN112041308A (en) Co-crystals
CN104873501A (en) Sulbactam sodium composition for treating infectious diseases
CN104337775A (en) Naproxen injection
CN103113390B (en) Sulbactam sodium compound and medical composition of sulbactam sodium compound and mezlocillin sodium
JP2009209048A (en) Medicinal magnesium oxide
CN103893132B (en) A kind of cefdinir granules and preparation technology thereof
CN108014091A (en) A kind of new cefmetazole for injection
CN114209656A (en) Florfenicol soluble powder and preparation method thereof
CN109620804B (en) Ceftriaxone sodium powder injection preparation for injection and preparation method thereof
CN102718779A (en) Ceftizoxime sodium for injection and preparation method thereof as well as synthetic method for ceftizoxime sodium serving as crude drug
CN104434916A (en) Compound naproxen injection
Kalmer et al. Evaluation of the effect of polymer composition on the rheological, mechanical properties and drug-released behavior of novel Eudragit L100-55/gelatin gastro-resistance uncoated capsule
CN105380909B (en) A kind of florfenicol soluble powder and preparation method thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20150218